Loading…
Anti-dyslipidemic and Antioxidant Potentials of Methanol Extract of Kalanchoe crenata Whole Plant in Streptozotocin-induced Diabetic Nephropathy in Rats
Purpose: The activity of the methanol extract of the whole plant of Kalanchoe crenata (MEKC) was studied for the treatment of diabetes-induced nephropathy in rats. Methods: Five-day old Wistar rats received a single intraperitoneal streptozotocin injection (90 μg/kg body weight) to induce diabetes....
Saved in:
Published in: | Tropical journal of pharmaceutical research 2012-10, Vol.11 (5) |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Purpose: The activity of the methanol extract of the whole plant of
Kalanchoe crenata (MEKC) was studied for the treatment of
diabetes-induced nephropathy in rats. Methods: Five-day old Wistar
rats received a single intraperitoneal streptozotocin injection (90
μg/kg body weight) to induce diabetes. Kidney disease onset in the
rats was observed six weeks after diabetes induction. The rats were
orally administered MEKC (0, 50 and 68 mg/kg) or glibenclamide (5
mg/kg), once daily for 6 weeks. Blood and urine glucose, proteins,
lipids, creatinine, malondialdehyde (MDA), superoxide dismutase (SOD)
and catalase (CAT) were then evaluated. Results: After 6 weeks of
treatment, 50 and 68 mg/kg MEKC, and glibenclamide significantly (p
< 0.01) decreased glycaemia (-35, -44 and -39 %), glycosuria (-38,
-47 and -61 %) and proteinuria (-82, -80 and -72 %) in
diabetes-nephropathic rats. The extract (68 mg/kg) decreased MDA by up
to -44 % (blood), - 35 % (liver) and -34 % (kidney); increased SOD up
to 257 % (blood), 116 % (liver) and 118 % (kidney); and CAT by up to
176 % (blood), 78 % (liver) and 96 % (kidney) in the rats, compared
with nephropathic control. The extract (50 and 68 mg/kg, respectively)
lowered (p < 0.01) total cholesterolemia (-24 and - 27 %), blood
triglycerides (-55 and -54 %), blood LDL cholesterol (-48 and -59 %),
but increased blood HDL cholesterol (71 and 58 %). Overall, atherogenic
index was decreased by 31 %. Conclusion: The results indicate that
MEKC holds promise for the development of a standardized phytomedicine
for diabetes mellitus and kidney disease treatment. |
---|---|
ISSN: | 1596-5996 1596-9827 |
DOI: | 10.4314/tjpr.v11i5.10 |